BRPI0517795A8 - modificação sítio-dirigida de fviii - Google Patents
modificação sítio-dirigida de fviiiInfo
- Publication number
- BRPI0517795A8 BRPI0517795A8 BRPI0517795A BRPI0517795A BRPI0517795A8 BR PI0517795 A8 BRPI0517795 A8 BR PI0517795A8 BR PI0517795 A BRPI0517795 A BR PI0517795A BR PI0517795 A BRPI0517795 A BR PI0517795A BR PI0517795 A8 BRPI0517795 A8 BR PI0517795A8
- Authority
- BR
- Brazil
- Prior art keywords
- site
- fviii
- directed modification
- eviii
- polyethylene glycol
- Prior art date
Links
- 230000004048 modification Effects 0.000 title abstract 2
- 238000012986 modification Methods 0.000 title abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 230000002947 procoagulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
modificação sítio-dirigida de fviii. esta invenção se refere a muteinas de fator viii que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de n-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. os conjugados de muteina conservam atividade pró-coagulante de eviii e têm propriedades fa rmacocinéticas aperfeiçoadas.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122016022033A BR122016022033B8 (pt) | 2004-11-12 | 2005-11-14 | conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62727704P | 2004-11-12 | 2004-11-12 | |
US60/627,277 | 2004-11-12 | ||
PCT/US2005/041205 WO2006053299A2 (en) | 2004-11-12 | 2005-11-14 | Site-directed modification of fviii |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0517795A BRPI0517795A (pt) | 2008-10-21 |
BRPI0517795A8 true BRPI0517795A8 (pt) | 2018-12-26 |
BRPI0517795B1 BRPI0517795B1 (pt) | 2020-03-31 |
BRPI0517795B8 BRPI0517795B8 (pt) | 2021-05-25 |
Family
ID=36337298
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016022033A BR122016022033B8 (pt) | 2004-11-12 | 2005-11-14 | conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica |
BRPI0517795A BRPI0517795B8 (pt) | 2004-11-12 | 2005-11-14 | conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122016022033A BR122016022033B8 (pt) | 2004-11-12 | 2005-11-14 | conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica |
Country Status (32)
Country | Link |
---|---|
US (4) | US7632921B2 (pt) |
EP (9) | EP2772500B1 (pt) |
JP (5) | JP2008524117A (pt) |
KR (7) | KR101468345B1 (pt) |
CN (6) | CN105753968A (pt) |
AU (1) | AU2005304622B2 (pt) |
BR (2) | BR122016022033B8 (pt) |
CA (1) | CA2586379C (pt) |
CY (3) | CY1119292T1 (pt) |
DK (3) | DK2371856T3 (pt) |
ES (4) | ES2821832T3 (pt) |
FR (1) | FR19C1031I2 (pt) |
HK (3) | HK1117875A1 (pt) |
HN (1) | HN2007015683A (pt) |
HR (2) | HRP20180481B1 (pt) |
HU (5) | HUE059193T2 (pt) |
IL (3) | IL182903A (pt) |
LT (5) | LT2371856T (pt) |
LU (1) | LUC00118I2 (pt) |
MA (1) | MA29663B1 (pt) |
MX (2) | MX2007005466A (pt) |
NL (1) | NL300989I2 (pt) |
NO (3) | NO345800B1 (pt) |
NZ (1) | NZ555032A (pt) |
PH (2) | PH12014500352A1 (pt) |
PL (3) | PL2363414T3 (pt) |
PT (4) | PT2363414T (pt) |
RU (1) | RU2423380C2 (pt) |
SI (4) | SI2363414T1 (pt) |
UA (1) | UA95225C2 (pt) |
WO (1) | WO2006053299A2 (pt) |
ZA (1) | ZA200703696B (pt) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
AU2005260763B2 (en) * | 2004-06-30 | 2011-12-22 | Nektar Therapeutics | Polymer-factor IX moiety conjugates |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
ES2821832T3 (es) | 2004-11-12 | 2021-04-27 | Bayer Healthcare Llc | Modificación de FVIII dirigida al sitio |
JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
RU2008145084A (ru) * | 2006-05-24 | 2010-06-27 | Ново Нордиск Хелс Кеа Аг (Ch) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo |
WO2008011633A2 (en) | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
CA2682897C (en) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
EP2222329A1 (en) * | 2007-11-09 | 2010-09-01 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
US20110077202A1 (en) | 2008-05-16 | 2011-03-31 | Bayer Healthcare Llc | Targeted Coagulation Factors and Method of Using the Same |
BRPI0913374A2 (pt) * | 2008-06-04 | 2015-11-24 | Bayer Healthcare Llc | muteínas fviii para tratamento de doença de von willebrand |
US8575104B2 (en) | 2008-06-24 | 2013-11-05 | Csl Behring Gmbh | Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
CA2738679A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
KR20110093775A (ko) * | 2008-11-03 | 2011-08-18 | 바이엘 헬스케어 엘엘씨 | 혈우병 치료 방법 |
EP2368124A4 (en) * | 2008-11-24 | 2012-09-19 | Bayer Healthcare Llc | METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY |
WO2010083536A1 (en) * | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
PT2393828T (pt) | 2009-02-03 | 2017-01-18 | Amunix Operating Inc | Polipéptidos recombinantes estendidos e composições que compreendem os mesmos |
WO2010102886A1 (en) * | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
CA2755395C (en) * | 2009-03-20 | 2015-02-24 | Hanmi Holdings Co., Ltd. | Method for preparing a site-specific physiologically active polypeptide conjugate |
CN102427823A (zh) * | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | 因子viii变体及使用方法 |
PL2459224T3 (pl) | 2009-07-27 | 2017-08-31 | Baxalta GmbH | Koniugaty białka związanego z krzepnięciem krwi |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CN102573920B (zh) | 2009-07-27 | 2015-01-14 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
JP5908401B2 (ja) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血液凝固タンパク質複合体 |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
JP5813641B2 (ja) * | 2009-08-24 | 2015-11-17 | アムニクス オペレーティング インコーポレイテッド | 凝固第ix因子組成物ならびにそれを製造および使用する方法 |
PL3326643T3 (pl) | 2009-12-06 | 2021-10-25 | Bioverativ Therapeutics Inc. | Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
CN102770449B (zh) | 2010-02-16 | 2016-02-24 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
RS59827B1 (sr) * | 2010-02-21 | 2020-02-28 | Bayer Healthcare Llc | Metoda za aktiviranje i konjugovanje biomolekula |
MX365521B (es) | 2010-04-15 | 2019-06-06 | Oligasis Star | Polimeros que contienen zwiteriones de alto peso molecular. |
GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
EP3508573A1 (en) | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
US9150637B2 (en) | 2010-11-05 | 2015-10-06 | Baxalta Inc. | Variant of antihemophilic factor VIII having increased specific activity |
WO2012079979A1 (en) * | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Aqueous factor viii solution |
CN103269723B (zh) | 2010-12-22 | 2017-04-05 | 百深有限责任公司 | 用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法 |
WO2012166622A1 (en) | 2011-05-27 | 2012-12-06 | Baxter International Inc. | Therapeutic proteins with increased half-life and methods of preparing same |
SI2717898T1 (sl) | 2011-06-10 | 2019-07-31 | Bioverativ Therapeutics Inc. | Spojine prokoagulantov in metode za njihovo uporabo |
AR087020A1 (es) | 2011-07-01 | 2014-02-05 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos |
DK3513804T3 (da) | 2011-07-08 | 2022-06-20 | Bioverativ Therapeutics Inc | Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf |
JP6352806B2 (ja) | 2011-09-23 | 2018-07-04 | ノヴォ ノルディスク アー/エス | 新規のグルカゴン類似体 |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
HUE043537T2 (hu) * | 2012-02-15 | 2019-08-28 | Bioverativ Therapeutics Inc | Rekombináns VIII faktor fehérjék |
EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
PL3564260T3 (pl) | 2012-02-15 | 2023-03-06 | Bioverativ Therapeutics Inc. | Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania |
EP2666782A1 (en) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
EP3693000B1 (en) | 2012-06-08 | 2022-03-02 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
WO2014008480A2 (en) | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
EP3446700A1 (en) | 2012-10-30 | 2019-02-27 | Bioverativ Therapeutics Inc. | Methods of using fviii polypeptide |
SG10201913874TA (en) | 2013-03-15 | 2020-03-30 | Biogen Ma Inc | Factor ix polypeptide formulations |
WO2014144795A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor viii polypeptide formulations |
US20160030524A1 (en) * | 2013-03-15 | 2016-02-04 | Bayer Healthcare Llc | Recombinant factor viii formulations |
BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子viii-xten融合物及其用途 |
EP3033098B1 (en) | 2013-08-14 | 2022-06-22 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
EP3041513B1 (en) | 2013-09-08 | 2020-08-05 | Kodiak Sciences Inc. | Factor viii zwitterionic polymer conjugates |
EP3060242A1 (en) * | 2013-10-22 | 2016-08-31 | DBV Technologies | Method of treating haemophilia by inducing tolerance to blood factors |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
RU2546297C1 (ru) * | 2013-11-19 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, улучшающее реологические свойства крови |
EP4332839A2 (en) | 2013-12-06 | 2024-03-06 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
AU2015207472B2 (en) * | 2014-01-20 | 2018-11-22 | Octapharma Ag | A process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII:Ag |
JP6609561B2 (ja) | 2014-02-04 | 2019-11-20 | バイオジェン・エムエイ・インコーポレイテッド | 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用 |
EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
EA038573B1 (ru) | 2014-03-24 | 2021-09-16 | Биовератив Терапьютикс Инк. | Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения |
WO2015154090A1 (en) * | 2014-04-04 | 2015-10-08 | Bloodworks | Routine laboratory and point-of-care (poc) testing for hemostasis |
WO2015157335A1 (en) | 2014-04-10 | 2015-10-15 | Bayer Healthcare Llc | Compounded media powder formulation and method of preparation of liquid medium for cell culture |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
WO2016000039A1 (en) | 2014-07-02 | 2016-01-07 | Csl Limited | Modified von willebrand factor |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
CN107406493B (zh) | 2015-03-06 | 2021-08-13 | 康诺贝林伦瑙有限公司 | 具有改善的半衰期的经修饰的血管性血友病因子 |
ES2774011T3 (es) | 2015-05-22 | 2020-07-16 | CSL Behring Lengnau AG | Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia |
US10772936B2 (en) | 2015-05-22 | 2020-09-15 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
RU2018128582A (ru) | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
CA3008448A1 (en) | 2016-01-07 | 2017-07-13 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
JP7235511B2 (ja) * | 2016-06-24 | 2023-03-08 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | 組換え型一本鎖fviiiおよびその化学コンジュゲート |
KR20190073576A (ko) | 2016-11-11 | 2019-06-26 | 체에스엘 베링 렝나우 아게 | 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 |
CA3043250A1 (en) | 2016-11-11 | 2018-05-17 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
CA3043702A1 (en) | 2016-11-16 | 2018-05-24 | Bayer Healthcare Llc | Red blood cell targeted factor viii and method of using the same |
AU2017368328A1 (en) | 2016-12-02 | 2019-07-18 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
CN110520150A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 使用嵌合凝血因子治疗血友病性关节病的方法 |
EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
US20190375822A1 (en) | 2018-05-18 | 2019-12-12 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021091881A1 (en) * | 2019-11-04 | 2021-05-14 | The Trustees Of Columbia University In The City Of New York | High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof |
WO2021113800A1 (en) * | 2019-12-06 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
EP0294910B1 (en) | 1987-06-12 | 1996-09-11 | Immuno Ag | Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
AU2473388A (en) * | 1987-11-16 | 1989-06-22 | Scripps Clinic And Research Foundation | Treatment of factor viii inhibitors |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
DE69333974T2 (de) | 1992-10-02 | 2006-08-03 | Genetics Institute, LLC, Cambridge | Zusammensetzung, welche den Koagulationsfaktor VIII beinhaltet; Verfahren zu deren Herstellung und die Benutzung eines Oberflächenaktiven Stoffes als Stabilisator |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
JPH09504174A (ja) | 1993-10-29 | 1997-04-28 | インサイト ファーマシューティカルズ,インク. | プロテアーゼネキシン1変異体を含むキメラ蛋白 |
IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
EP0776530A4 (en) * | 1995-06-21 | 1998-06-10 | Motorola Inc | METHOD AND ANTENNA PRODUCING AN OMNIDIRECTIONAL RADIATION DIAGRAM |
AU6486196A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AT403438B (de) | 1996-05-24 | 1998-02-25 | Immuno Ag | Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität |
US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
EP0964702B1 (en) * | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
EP1881005B1 (en) | 1997-07-14 | 2013-04-03 | Bolder Biotechnology, Inc. | Derivatives of G-CSF and related proteins |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
JP2001520198A (ja) * | 1997-10-17 | 2001-10-30 | ハーベスト・テクノロジーズ・コーポレイション | 血小板富有血漿からの成長因子富有化フィブリノーゲン濃縮物の調製 |
EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
DK1129186T4 (da) | 1998-11-10 | 2017-02-06 | Stichting Sanquin Bloedvoorziening | Et faktor VIII-polypeptid med faktor VIII:C-aktivitet |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
ATE526401T1 (de) | 1999-01-14 | 2011-10-15 | Bolder Biotechnology Inc | Verfahren zur herstellung von proteinen mit freien cysteinresten |
WO2000071714A2 (en) | 1999-05-24 | 2000-11-30 | The American National Red Cross | Methods of reducing factor viii clearance and compositions therefor |
ES2325877T3 (es) * | 2000-02-11 | 2009-09-23 | Bayer Healthcare Llc | Moleculas de tipo factor vii o viia. |
MXPA03002256A (es) | 2000-09-19 | 2003-09-10 | Univ Emory | Factor viii modificado. |
US7615622B2 (en) | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
ES2432967T3 (es) * | 2001-03-22 | 2013-12-05 | Novo Nordisk Health Care Ag | Derivados del Factor VII de coagulación |
AU2002312660A1 (en) | 2001-05-31 | 2002-12-16 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
DE60230456D1 (de) | 2001-10-05 | 2009-01-29 | Expression Therapeutics Llc | Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren |
CA2482926A1 (en) | 2002-04-18 | 2003-10-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified factor viii |
US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
ATE399185T1 (de) | 2002-12-31 | 2008-07-15 | Nektar Therapeutics Al Corp | Maleinsäureamid polymerderivate und ihre biokonjugate |
DE60329627D1 (de) | 2002-12-31 | 2009-11-19 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
CA2509939C (en) | 2003-01-06 | 2013-05-21 | Nektar Therapeutics Al, Corporation | Thiol-selective water-soluble polymer derivatives |
HUE058897T2 (hu) | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polimer VIII-as faktor egység konjugátumok |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180054A1 (en) * | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20050107297A1 (en) * | 2003-05-12 | 2005-05-19 | Holmes Christopher P. | Novel poly(ethylene glycol) modified compounds and uses thereof |
LT2644206T (lt) | 2003-05-23 | 2019-05-27 | Nektar Therapeutics | Peg dariniai, susidedantys iš dviejų peg grandinių |
EP1502921A1 (en) | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
US20050123997A1 (en) | 2003-10-30 | 2005-06-09 | Lollar John S. | Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
ATE463572T1 (de) | 2003-12-03 | 2010-04-15 | Univ Rochester | Rekombinanter faktor viii mit erhöhter spezifischer aktivität |
WO2006027111A1 (en) | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
ES2821832T3 (es) | 2004-11-12 | 2021-04-27 | Bayer Healthcare Llc | Modificación de FVIII dirigida al sitio |
EP1871801A2 (en) | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Blood coagulation fviii analogues |
KR20080108147A (ko) | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 viii |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
-
2005
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es active Active
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko active Protection Beyond IP Right Term
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en active Active
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko active IP Right Grant
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en active Active
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 CA CA2586379A patent/CA2586379C/en active Active
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en active Active
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko active Protection Beyond IP Right Term
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en active Active
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Application Discontinuation
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en active Active
- 2005-11-14 PH PH12014500352A patent/PH12014500352A1/en unknown
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr active IP Right Grant
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh active Active
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es active Active
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Application Discontinuation
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh active Active
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es active Active
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko active IP Right Grant
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh active Active
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh active Active
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en active Search and Examination
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en unknown
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en active Active
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko active IP Right Grant
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en active Active
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es active Active
-
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-08 HR HRP20070268AA patent/HRP20070268B1/hr active IP Right Grant
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
-
2008
- 2008-07-15 HK HK08107795.4A patent/HK1117875A1/xx unknown
-
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
-
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja active Active
-
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en active Active
- 2013-08-13 HK HK13109463.4A patent/HK1182121A1/xx unknown
-
2014
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja active Active
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
-
2016
- 2016-06-13 HK HK16106727.9A patent/HK1218718A1/zh unknown
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja active Active
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja active Active
-
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
-
2019
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I1/el unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
-
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517795A8 (pt) | modificação sítio-dirigida de fviii | |
CY1113869T1 (el) | Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf | |
EP3406347A3 (en) | Xten conjugate compositions and methods of making same | |
MX2010007150A (es) | Formulaciones del factor de von-willebrand recombinante. | |
DK2132221T3 (da) | Template-fikserede peptidomimetika | |
CY1118360T1 (el) | Παρατεταμενης διαρκειας τοπικη αναισθητικη συνθεση η οποια περιεχει saib | |
CY1108843T1 (el) | 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων | |
WO2006103298A3 (en) | Blood coagulation fviii analogues | |
ATE493386T1 (de) | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate | |
UA92603C2 (ru) | Фармацевтическая композиция для лечения тромбоза | |
LU91989I2 (fr) | Bydureon | |
GB201009493D0 (en) | Modified recombinant factor viii and von willebrand factor and methods of use | |
MX2012012683A (es) | Factor viii conjugado para coagulacion de la sangre. | |
BRPI0620436B8 (pt) | compostos miméticos de lisina modificados, composição farmacêutica e uso | |
ATE487501T1 (de) | Hämostatische zusammensetzungen und vorrichtungen | |
CY1112682T1 (el) | Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων | |
DE602004019546D1 (de) | Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen | |
MY160510A (en) | Polyethylene gycol conjugated blood coagulation factor viia | |
GEP20115201B (en) | Cinnamoyl-piperazine derivatives and their use as par- i antagonists | |
ATE458740T1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten | |
BRPI0414008B8 (pt) | compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula | |
CY1106617T1 (el) | Φαρμακευτικη συνθεση περιλαμβανουσα συμπλοκο ψευδαργυρου-υαλουρονικου για τη θεραπεια σκληρυνσης κατα πλακας | |
MY151329A (en) | Site-directed modification of fviii | |
MY173864A (en) | Site-directed modification of fviii | |
MY181129A (en) | Site-directed modification of fviii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |